Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. The disease is incurable; although over the past decade there have been significant improvements in therapy, driven by a greater understanding of pathophysiology. MM represents about 0.8–1% of all cancer cases worldwide and approximately 10% of all hematological cancers, with incidence rates ranging from 0.4 to 5 per 100,000 persons in different parts of the world. Without any treatment, the median survival of a myeloma patient is about six months, but this can be extended with the use of various forms of treatment. There are now five classes of drugs used in the treatment of myeloma: immunomodulatory drugs, chemotherapy, proteasome drugs, Histone Deacetylase (HDAC) inhibitors and steroids. Many of the notable drugs in these classes were approved over the past 10–15 years. Treatment using these novel drugs and high-dose chemotherapy with hematopoietic Stem-Cell Transplant (SCT) has been shown to improve median survival to five years, which makes this the current standard therapy. However, many patients suffer relapse or develop treatment resistance, leaving a need to develop safe and effective treatments that prolong the duration of remission and improve survival. Complete report on “Multiple Myeloma Therapeutics” addition with 18 market data tables and 45 figures, spread across 117 pages is http://www.rnrmarketresearch.com/multiple-myeloma-therapeutics-in-asia-pacific-markets-to-2021-growth-driven-by-rising-prevalence-continued-success-of-velcade-revlimid-and-emerging-supplementary-treatments-market-report.html . Scope: • What are the treatment options available for myeloma, providing an overview of the front-line, second-line and third-line therapies available? • What are the dominant mechanisms of action across marketed products? • Which products are approved currently in each country and which ones are likely to be launched within the forecast period? • Which product is used more in each country? • Will there be any label expansions of existing market leaders in any of the countries? • What are the various epidemiology trends in each country? • What factors contribute to the overall epidemiology? • What are the various pipeline products based on molecule type, mechanism of action and stage of development? • Which class is most prominent within the pipeline? • Do the pipeline molecules offer an advantage over commercially proven mechanisms? • What are the late-pipeline products expected to be launched in each country in the near future? • How do failure rates vary by product stage of development, molecule type, and mechanism of action? • How do other factors such as average trial duration and trial size influence the costs and risks associated with product development? • What are the current promising pipeline drugs and their efficacy data? • Which markets make the most significant contribution to the current market size? • What are the incidence, diagnosis and treatment trends in these markets? • What are the factors responsible for difference in the treatment patterns within the four markets? • Which factors will influence growth rates? • Will new market entrants lead to substantial changes in annual therapy costs? • Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs? • Will the patent expiration be offset by the approval of new therapies? Request for sample: http://www.rnrmarketresearch.com/contacts/request-sample?rname=437609 . (This is a premium report price at US$4995 for a single user PDF license) Reasons to buy: • Understand the clinical context of MM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options. • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need. • Appreciate key pipeline trends in molecule type, administration route, mechanism of action, and novelty. • Consider market opportunities and potential risks by examining trends in clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action. • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential by examining clinical trial data and multi-scenario product forecast projections. • Compare treatment usage patterns, annual therapy costs, and market growth projections for India, China, Australia and Japan. • Discover trends in licensing and co-development deals concerning MM products and identify the major strategic consolidations that have shaped the commercial landscape. Explore More Research Report on Cancer Therapeutics Market. Cancer has always being considered to be one of the dreadful diseases because of the deficiency in effective therapeutics. Every new day seems to be an opportunity for the researchers to find out a new reagent that can relieve the patients from the immense pain due to the malignant out growth. In fact the pharmaceutical industries have helped those inventions to reach out to the sufferers as fast as possible. Then only the invention will find its goal successfully: heal the mankind. Thus various clinical trials of cancer therapeutics are being performed to bring the tremendous developments in to account. You might make the high prices to be the result of the new cancer treatment medicines entering the market. In recent years, the promising discoveries are being licensed as fast as possible such that it does not delay in reaching out to the ailing hands. You can also make this the sole reason for the pharmaceutical industry to reach its pinnacle during last few years.
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries